Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease

Cancer Chemother Pharmacol. 2018 Jan;81(1):179-182. doi: 10.1007/s00280-017-3479-2. Epub 2017 Nov 23.


Purpose: Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old metastatic colorectal cancer patient with chronic kidney injury with a glomerular filtration rate of approximately 11 mL/min.

Methods: Pharmacokinetic parameters, including dose-normalized area under the curve, clearance and elimination half-life (T 1/2) after the 11th and 12th infusions were estimated using trapezoidal non-compartmental methods. Data were compared to previous reported pharmacokinetic data from studies in patients with normal renal function.

Results: The results show that the pharmacokinetic data in this patient with kidney failure are comparable to those in patients with adequate renal function. Moreover the treatment was well tolerated in this patient.

Conclusion: This study suggests that panitumumab can be safely used in cancer patients with renal impairment without dose adjustment.

Keywords: Colorectal cancer; Panitumumab; Pharmacokinetics; Renal insufficiency.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / pharmacokinetics*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Area Under Curve
  • Colorectal Neoplasms / complications*
  • Colorectal Neoplasms / drug therapy*
  • Dose-Response Relationship, Drug
  • Glomerular Filtration Rate
  • Half-Life
  • Humans
  • Male
  • Middle Aged
  • Panitumumab / administration & dosage
  • Panitumumab / adverse effects*
  • Panitumumab / pharmacokinetics*
  • Panitumumab / therapeutic use
  • Renal Insufficiency, Chronic / complications*
  • Renal Insufficiency, Chronic / metabolism
  • Renal Insufficiency, Chronic / physiopathology


  • Antineoplastic Agents, Immunological
  • Panitumumab